The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: To assess the association of compliance with treatment (medication and clinic appointments) and all-cause mortality in people with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS: Data were extracted from U.K. general practice records and included patients (N = 15,984) who had diagnostic codes indicative of type 2 diabetes or who had received a prescription for an oral antidiabetic agent and were treated with insulin. Records in the 30 months before the index date were inspected for clinical codes (recorded at consultation) indicating medication noncompliance or medical appointment nonattendance. Noncompliance was defined as missing more than one scheduled visit or having at least one provider code for not taking medications as prescribed. Relative survival postindex date was compared by determining progression to all-cause mortality using Cox proportional hazards models. RESULTS: Those identified as clinic nonattenders were more likely to be smokers, younger, have higher HbA1c, and have more prior primary care contacts and greater morbidity (P < 0.001). Those identified as medication noncompliers were more likely to be women (P = 0.001), smokers (P = 0.014), and have higher HbA1c, more prior primary care contacts, and greater morbidity (all P < 0.001). After adjustment for confounding factors, medication noncompliance (hazard ratio 1.579 [95% CI 1.167–2.135]), clinic nonattendance of one or two missed appointments (1.163 [1.042–1.299]), and clinic nonattendance of greater than two missed appointments (1.605 [1.356–1.900]) were independent risk factors for all-cause mortality. CONCLUSIONS: Medication noncompliance and clinic nonattendance, assessed during routine care by primary care physicians or their staff, were independently associated with increased all-cause mortality in patients with type 2 diabetes receiving insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109
Karter, A. J., Ackerson, L. M., Darbinian, J. A., D’Agostino, R. B., Ferrara, A., Liu, J., & Selby, J. V. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00742-2 · Cited by 595
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Self-citationAdherence to pharmacologic therapy in patients with type 2 diabetes mellitus
Rubin, R. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.012 · Cited by 406
Self-citationSecrest, A. M., Becker, D. J., Kelsey, S. F., LaPorte, R. E., & Orchard, T. J. (2010) · Diabetes · doi:10.2337/db10-0862 · Cited by 358
Patient Adherence Improves Glycemic Control
Rhee, M. K., Slocum, W., Ziemer, D. C., Culler, S. D., Cook, C. B., El-Kebbi, I. M., Gallina, D. L., Barnes, C., & Phillips, L. S. (2005) · The Diabetes Educator · doi:10.1177/0145721705274927 · Cited by 339
Cited by
Polonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784
“7 Similarly, Ho et al 8 reported a significant association between poor medication adherence in T2D and all-cause mortality over time (odds ratio 1.8; P 0.001).”
InfluentialAdherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Gonzalez, J. S., Tanenbaum, M. L., & Commissariat, P. V. (2016) · American Psychologist · doi:10.1037/a0040388 · Cited by 354
“…associated with worse glycemic control (e.g., Feldman et al., 2014; Hood, Peterson, Rohan, & Drotar, 2009; Schectman, Nadkarni, & Voss, 2002) and increased risk for hospitalization, complications, and mortality (e.g., Cho et al., 2011; Currie et al., 2012; Ho et al., 2006; Kuo et al., 2003).”
BackgroundPan, A., Wang, Y., Talaei, M., & Hu, F. B. (2015) · Circulation · doi:10.1161/circulationaha.115.017926 · Cited by 343
Weber, D. R., Haynes, K., Leonard, M. B., Willi, S. M., & Denburg, M. R. (2015) · Diabetes Care · doi:10.2337/dc15-0783 · Cited by 274
McGovern, A., Tippu, Z., Hinton, W., Munro, N., Whyte, M., & de Lusignan, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13160 · Cited by 166
Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12902 · Cited by 111
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101
Kostev, K., Ouwens, M., Grandy, S., Johnsson, K. M., & Qiao, Q. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s99732 · Cited by 92
“14).(8) Consistent with findings from this study in Germany, a retrospective cohort study of 6 months’ adherence to GLP-1RAs in patients with type 2 diabetes based on a US administrative claim data showed that patients treated with exenatide once weekly had a statistically significantly greater multivariable-adjusted…”
Kulzer, B., Daenschel, W., Daenschel, I., Schramm, W., Messinger, D., Weissmann, J., Vesper, I., Parkin, C. G., & Heinemann, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.09.002 · Cited by 77
Brod, M., Rana, A., & Barnett, A. H. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.743458 · Cited by 77
A Systematic Review of Insulin Adherence Measures in Patients with Diabetes
Stolpe, S., Kroes, M. A., Webb, N., & Wisniewski, T. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1224 · Cited by 77
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Gourzoulidis, G., Kourlaba, G., Stafylas, P., Giamouzis, G., Parissis, J., & Maniadakis, N. (2017) · Health Policy · doi:10.1016/j.healthpol.2017.02.008 · Cited by 62
Leiter, L. A., Boras, D., & Woo, V. C. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.270 · Cited by 48
Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40
Ekberg, N. R., Hartvig, N. V., Kaas, A., Møller, J. B., & Adolfsson, P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221104142 · Cited by 36
Distress and Type 2 Diabetes Self-Care: Putting the Pieces Together
Hoogendoorn, C. J., Schechter, C. B., Llabre, M. M., Walker, E. A., & Gonzalez, J. S. (2021) · Annals of Behavioral Medicine · doi:10.1093/abm/kaaa070 · Cited by 28
Svensson, A., Toll, A., Lebrec, J., Miftaraj, M., Franzén, S., & Eliasson, B. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14276 · Cited by 17
Abi Mosleh, K., Salameh, Y., Ghusn, W., Jawhar, N., Mundi, M. S., Collazo‐Clavell, M. L., Kendrick, M. L., & Ghanem, O. M. (2024) · Clinical Obesity · doi:10.1111/cob.12689 · Cited by 5
Metadata
- Authors
- Currie, C. J., Peyrot, M., Morgan, C. L., Poole, C. D., Jenkins-Jones, S., Rubin, R. R., Burton, C. M., & Evans, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-05-11
- Volume
- 35
- Issue
- 6
- Pages
- 1279-1284
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2036387352
- Cited by
- 252
- References
- 40
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.